FindTrial
Sign In

A prospective, randomized, open, multicenter clinical trial of decitabine or azacytidine combined with CHG regimen in elderly patients with acute myeloid leukemia

A prospective, randomized, open, multicenter clinical trial of decitabine or azacytidine combined with CHG regimen in elderly patients with acute myeloid leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034297
Enrollment
Unknown
Registered
2020-07-01
Start date
2020-07-23
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Group A:DCHG scheme
Group B:ACHG scheme

Sponsors

Shanxi Bethune Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Aged >= 60 years, both male and female; 2) Patients with acute myeloid leukemia diagnosed by morphology, immunology and genetics of bone marrow cells were diagnosed according to WHO diagnostic criteria (except for aml-m3 patients). 3) The proportion of bone marrow progenitor cells was more than 30%; 4) The ECOG-ps score of the eastern oncology collaboration group was 0-2.

Exclusion criteria

Exclusion criteria: 1) Accompanied by cerebral hemorrhage; 2) Pregnancy; 3) Mental illness or other conditions that cannot be carried out as planned; 4) Severe arrhythmia, abnormal ECG (QT > 500ms).

Design outcomes

Primary

MeasureTime frame
Complete remission rate;Relapse Rate;—

Secondary

MeasureTime frame
Event free survival;Overall survival;Peripheral blood primitive cell count in agranulocytosis;—

Countries

China

Contacts

Public ContactTao Wang
wangtao99699@163.com+86 13835175119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026